underwent LLETZ. All women who had initial successful treatment were included in further analysis.

Follow-up consisted of regular pap smears according to Dutch guidelines during two years. Successful treatment was defined as no histologic CIN 2/3 diagnosis during follow-up.

**Results**

A total of 84 women were included in the analysis (27 from the imiquimod group and 57 from the LLETZ group). CIN2/3 was diagnosed in one woman (2%) in LLETZ group and two women in the imiquimod group (7%), all underwent additional LLETZ treatment (p=0.26). For both entire groups, HPV status at 2 year follow-up was similar.

CIN grade at inclusion, HPV status at short term follow-up, age, parity and smoking were not identified as factors associated with successful treatment.

**Conclusions**

Disease recurrence of high-grade CIN two years after successful treatment with imiquimod is infrequent and is not statistically different from LLETZ treatment. This indicates a lasting effectiveness of imiquimod treatment.

---

**EPV238/#131 IMPACT OF LYMPHADENECTOMY AND INTRAOPERATIVE TUMOR RUPTURE ON SURVIVAL IN EARLY STAGE MUCINOUS OVARIAN CANCERS**

1RS Kim*, 2A Madariaga, 1L Hogen, 1D Vicus, 1A Coven, 4C Parra-Herran, 5L Lheureux, 1L Gien, 1Princess Margaret Cancer Centre/University of Health Network/Sinai Health Systems, Gynecologic Oncology, Toronto, Canada; 2Princess Margaret Cancer Centre/University of Health Network/Sinai Health Systems, Medical Oncology, Toronto, Canada; 3Sunnybrook Health Sciences Centre, Gynecologic Oncology, Toronto, Canada; 4Brigham and Woman’s Hospital, Pathology, Boston, USA

Objectives The aim of the study was to investigate the prognostic significance of lymphadenectomy and intraoperative tumor rupture in patients with apparent stage I mucinous ovarian carcinoma (MOC).

Methods We conducted a retrospective cohort study of MOCs diagnosed between 1999–2019 at two tertiary cancer centers. Pathology was reviewed to rule out metastasis from gastrointestinal tract. Clinicopathologic details, five-year overall survival (OS) and recurrence free survival (RFS) were examined. Cox proportional hazard models were used to determine the association of lymphadenectomy and intraoperative rupture on survival.

Results of 149 with apparent stage I disease, 48 (32%) had pelvic and/or para-aortic lymphadenectomy, but only 1 patient with grade 2 disease was upstaged due to positive pelvic lymph nodes. Intraoperative rupture was documented in 52 (35%); these were more likely to have initial surgery performed by a non-gynecologic oncologist (48% vs. 11%; p<0.001). There were 20 recurrences in the cohort (13%; 9 grade 1, 6 grade 2, 4 grade 3), with the vast majority peritoneal (95%). On multivariable analysis, after adjusting for age, final stage, and use of adjuvant chemotherapy, there was no significant association between intraoperative rupture with OS (HR 2.2 (0.6–8.0), p=0.25) or RFS (HR 1.3 (0.5–3.3), p=0.63) or lymphadenectomy with OS (HR 0.9 (0.3–2.8), p=0.90) or RFS (HR 1.2 (0.5–3.0), p=0.73).

Conclusions In apparent stage I MOC, systematic lymphadenectomy has low utility, as few patients are upstaged and recurrence typically occurs in the peritoneum. Furthermore, intraoperative rupture does not independently confer a worse survival.

---

**EPV239/#263 EVALUATION OF THE IMPACT OF POSTOPERATIVE ADJUVANT THERAPY ON SURVIVAL AND RECURRENCE PATTERNS IN STAGE I-IV UTERINE CARCINOSARCOMA**

1J Mceachron*, 1Y-J Chen, 1N Zhou, 2C Goneliak, 3M Kanis, 1J Fehniger, 1YC Lee, 1SUNY Downstate Health Sciences University, Gynecologic Oncology, Brooklyn, USA; 2New York Presbyterian Brooklyn Methodist Hospital, Gynecologic Oncology, Brooklyn, USA

Objectives To evaluate differences in survival and recurrence patterns in stage I-IV uterine carcinosarcoma (UCS) patients treated with surgery followed by adjuvant chemotherapy (CT), radiation (RT) or both (chemoRT).

Methods A multicenter retrospective analysis of patients with surgically staged UCS receiving adjuvant therapy from 2000 to 2019 was conducted. Sites of recurrence were analyzed by adjuvant treatment modality using Pearson’s χ²-test. PFS and OS were calculated using Kaplan-Meier estimates. Multivariate analysis (MVA) was performed using Cox proportional hazards model.
Tumor size as a prognostic factor for mesonephric and mesonephric-like adenocarcinoma of the endometrium: A rare case series of 72 patients

Objective Mesonephric adenocarcinoma (MA) or mesonephric-like adenocarcinoma (MLA) is a rare tumor of the endometrium arising from regressed mesonephric duct. However, there is still a lack of evidence about their prognostic factors because of the rarity. Thus, we investigated prognostic factors of MA or MLA through the analysis of rare case series by using published reports.

Methods This study is a secondary analysis utilizing published literature. Through extensive search using PubMed, Embase and the Cochrane database, 65 patients with either MA or MLA were identified between years 1995 and 2020. A total of 72 patients were finally included after adding seven patients diagnosed with MA or MLA in our institute between 2000 and 2020. We evaluated clinicopathologic characteristics of all patients, and investigated prognostic factors affecting progression-free survival (PFS).

Results Patients with early-stage disease (n=41) had longer mean PFS than those with advanced-stage disease (n=31) (39 vs 14 months, p<0.01). Moreover, patients with tumor size ≤5 cm (n=16) had longer mean PFS that those with tumor size >5 cm (n=15; 49 vs 13 months; p=0.01). Univariate analyses revealed that advanced-stage disease, tumor size >5 cm and no systemic chemotherapy were factor affecting PFS (hazard ratios [HRs], 3.27, 5.88, 4.34; 95% confidence interval [CIs] 1.56–6.84, 1.26–27.33, 1.74–10.85. Finally, tumor size >5 cm was the only prognostic factor of worse PFS in multivariate analyses (HR 5.49; 95% CI 1.15–26.18).

Conclusions Tumor size >5 cm may be associated with worse PFS of MA or MLA of the endometrium.

Outcomes of laterally extended endopelvic resection in pelvic sidewall sarcoma: A single-institution experience

Objective This study aims to review tolerability and efficacy of laterally extended endopelvic resection (LEER) in patients with pelvic sidewall sarcoma.

Methods We retrospectively reviewed medical records of patients with pelvic sidewall sarcoma who underwent LEER between 2015 and to Mar. 2021. We collected data on clinicopathologic characteristics, surgery, perioperative management, and outcomes.